SCHEMBL3289378

SCHEMBL3289378

CC(=O)O[C@@H](C(=O)O)[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.48
USP2 O75604 1/20 0.46
SLCO1B1 Q9Y6L6 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 2/20 0.35
OR51E2 Q9H255 1/20 0.32
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP9 P14780 1/20 0.32
MMP13 P45452 1/20 0.32
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1656749 0.98 PDE4A (0.50) PDE4AUSP2SLCO1B1TDP1LMNA
SCHEMBL6142502 0.87 TDP1 (0.46) PDE4AUSP2SLCO1B1TDP1LMNA
SCHEMBL18451403 0.85 LMNA (0.44) PDE4AUSP2SLCO1B1TDP1LMNA
SCHEMBL9539845 0.84 PDE4A (0.40) PDE4AUSP2SLCO1B1TDP1LMNA
SCHEMBL8465610 0.82 PDE4A (0.54) PDE4AUSP2SLCO1B1TDP1LMNA
Potassium Ion SCHEMBL3187155 0.81 LMNA (0.50) PDE4AUSP2SLCO1B1TDP1LMNA
SCHEMBL8680823 0.81 PDE4A (0.52) PDE4AUSP2SLCO1B1TDP1LMNA
SCHEMBL6274785 0.81 PDE4A (0.52) PDE4AUSP2SLCO1B1TDP1LMNA
SCHEMBL15049970 0.81 PDE4A (0.52) PDE4AUSP2SLCO1B1TDP1LMNA
SCHEMBL7994016 0.80 PDE4A (0.57) PDE4AUSP2SLCO1B1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1536843-B1 RADIOLABELED COMPOUNDS AND LIPOSOMES AND THEIR METHODS OF MAKING AND USING THE SAME UNIV TEXAS (US) 2010-12-22 EP disclosed
US-7718160-B2 Radiolabeled compounds and liposomes and their method of making and using same THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-05-18 US disclosed
EP-1536843-A4 RADIOLABELED COMPOUNDS AND LIPOSOMES AND THEIR METHODS OF MAKING AND USING THE SAME UNIV TEXAS (US) 2009-01-14 EP disclosed
US-20050222396-A1 Radiolabeled compounds and liposomes and their method of making and using same PLUS THERAPEUTICS, INC. 2005-10-06 US disclosed
EP-1536843-A2 RADIOLABELED COMPOUNDS AND LIPOSOMES AND THEIR METHODS OF MAKING AND USING THE SAME BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) 2005-06-08 EP disclosed
WO-2004004635-A2 RADIOLABELED COMPOUNDS AND LIPOSOMES AND THEIR METHODS OF MAKING AND USING THE SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222396-A1 Radiolabeled compounds and liposomes and their method of making and using same LIPA, NPC1L1, GBA1 PDE4A 1089/4885USP2 1301/4885SLCO1B1 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.